| HOME >> MEDICINE >> TECHNOLOGY |
Medical Training and Practice Challenges 17
Shortcomings to Overcome 18
Limited Reimbursements by Third Party Payers - A Stumbling Block 18
Hurdles All the Way for Companies Eyeing Molecular Diagnostics 19
Product Marketing - Key to Commercial Success 20
Integration of Molecular Diagnostics into Therapeutics 20
Molecular Diagnostics - Moving from Centralization to
Decentralization 20
Migrating to Decentralized Format 21
Going Ahead with Decentralization 22
6. PRODUCT FACTS 22
Infectious Diseases Testing 22
Pharmacogenomics 23
Cancer Screening 23
7. CORPORATE DEVELOPMENTS 24
Vermillion, Johns Hopkins Ink Agreements to Develop Molecular
Diagnostic-Tests 24
Beckman Coulter Inks Licensing Agreements with National
University of Ireland 24
Roche Takes Over BioVeris 24
Siemens Acquires Dade Behring 24
DiagnoCure Acquires Catalyst Oncology 25
Burrill & Co Takes over Expression Diagnostics 25
Solis Acquires Bertrand 25
ParagonDx LLC Purchases Gentris Diagnostics 25
Beckman Collaborates to Discover CVD Symptoms 25
Exiqon to Take over Oncotech 26
Roche to Acquire Ventana 26
Qiagen Merges with Digene 26
Qiagen & Bio One Capital Collaborates 26
AGT & MAL Signs MoU 26
Qiagen Obtains Licenses to Real-Time PCR 27
Cepheid Purchases Sangtec 27
Source MDx Collaborates with Pfizer 27
Nanosphere Receives FDA Clearance for Second Molecular
Diagnostic Test 27
QIAGEN Acquires eGene 27
Quest Diagnostics Acquires AmeriPath 28
Mayo and ILMN Team up to Develop Molecular Diagnostics for
Complex- Diseases 28
CHEO and ILMN T
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |